Prognostic Factors for Patients With a Large Number of Hepatocellular Carcinoma Nodules.
A large number of hepatocellular carcinoma nodules
Overall survival
Sorafenib
Transarterial chemoembolization
Journal
Journal of clinical medicine research
ISSN: 1918-3003
Titre abrégé: J Clin Med Res
Pays: Canada
ID NLM: 101538301
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
21
11
2019
accepted:
09
12
2019
entrez:
4
2
2020
pubmed:
6
2
2020
medline:
6
2
2020
Statut:
ppublish
Résumé
The prognostic factors and treatment strategies for hepatocellular carcinoma (HCC) patients with a large number of tumor nodules have not been fully elucidated. Clinical factors influencing prognosis were investigated in HCC patients with 30 or more tumor nodules. Forty-six HCC patients with 30 or more tumor nodules participated in this study. None of them had vascular invasion and extrahepatic metastasis. Kaplan-Meier curve and Cox proportional hazard model were used for analysis. The median survival time of our patients was no more than 15 months, suggesting that patients with 30 or more tumor nodules may be regarded as a progressive subgroup showing poorer prognosis. In multivariate analysis, presence of between 30 and 59 tumor nodules (P = 0.002), male gender (P = 0.002), lower total bilirubin (total bilirubin < 1.0 mg/dL) (P = 0.011), transarterial chemoembolization (TACE) as an initial therapy (P = 0.027) and higher prothrombin time (P = 0.049) were significant independent factors for better overall survival. Among 39 patients who underwent TACE as an initial therapy, patients who received sorafenib therapy during follow-up showed better overall survival than those who did not (P = 0.026). Efficacy of sorafenib appeared to be more evident in patients who needed repeated transarterial treatment. In HCC patients with 30 or more tumor nodules, TACE as an initial therapy may be correlated with better prognosis. Sorafenib administration after the prior transarterial treatment may improve antitumor efficacy.
Sections du résumé
BACKGROUND
BACKGROUND
The prognostic factors and treatment strategies for hepatocellular carcinoma (HCC) patients with a large number of tumor nodules have not been fully elucidated. Clinical factors influencing prognosis were investigated in HCC patients with 30 or more tumor nodules.
METHODS
METHODS
Forty-six HCC patients with 30 or more tumor nodules participated in this study. None of them had vascular invasion and extrahepatic metastasis. Kaplan-Meier curve and Cox proportional hazard model were used for analysis.
RESULTS
RESULTS
The median survival time of our patients was no more than 15 months, suggesting that patients with 30 or more tumor nodules may be regarded as a progressive subgroup showing poorer prognosis. In multivariate analysis, presence of between 30 and 59 tumor nodules (P = 0.002), male gender (P = 0.002), lower total bilirubin (total bilirubin < 1.0 mg/dL) (P = 0.011), transarterial chemoembolization (TACE) as an initial therapy (P = 0.027) and higher prothrombin time (P = 0.049) were significant independent factors for better overall survival. Among 39 patients who underwent TACE as an initial therapy, patients who received sorafenib therapy during follow-up showed better overall survival than those who did not (P = 0.026). Efficacy of sorafenib appeared to be more evident in patients who needed repeated transarterial treatment.
CONCLUSIONS
CONCLUSIONS
In HCC patients with 30 or more tumor nodules, TACE as an initial therapy may be correlated with better prognosis. Sorafenib administration after the prior transarterial treatment may improve antitumor efficacy.
Identifiants
pubmed: 32010419
doi: 10.14740/jocmr4032
pmc: PMC6968922
doi:
Types de publication
Journal Article
Langues
eng
Pagination
26-35Informations de copyright
Copyright 2020, Abe et al.
Déclaration de conflit d'intérêts
All authors declare no conflict of interest related to this article.
Références
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Hepatology. 2011 Dec;54(6):2055-63
pubmed: 21898496
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
Clin Drug Investig. 2015 Nov;35(11):751-9
pubmed: 26446004
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Oncology. 2014;87 Suppl 1:32-6
pubmed: 25427731
Hepatology. 2005 Nov;42(5):1208-36
pubmed: 16250051
Oncology. 2014;87(6):330-41
pubmed: 25227534
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Hepatol Int. 2010 Mar 18;4(2):439-74
pubmed: 20827404
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Am J Gastroenterol. 2012 Apr;107(4):569-77; quiz 578
pubmed: 22158026
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Hepatol Int. 2017 Jan;11(1):105-114
pubmed: 27766479
Jpn J Radiol. 2014 May;32(5):260-5
pubmed: 24615165
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Liver Int. 2015 Feb;35(2):591-600
pubmed: 25290314
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Gastroenterology. 2006 Aug;131(2):461-9
pubmed: 16890600
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
Cancer Res. 2004 Oct 1;64(19):7099-109
pubmed: 15466206
J Gastroenterol Hepatol. 2015 Feb;30(2):358-63
pubmed: 25088668
Biometrika. 1965 Jun;52:203-23
pubmed: 14341275
Semin Liver Dis. 2012 Nov;32(4):348-59
pubmed: 23397536